You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
江蘇吳中(600200.SH):與索元生物簽署轉讓與許可協議 涉及研發項目重組人血管內皮抑素注射液
格隆匯 11-30 18:37

格隆匯 11 月 30日丨江蘇吳中(600200.SH)公佈,20201130日,公司全資子公司吳中醫藥與索元生物簽署了《轉讓與許可協議》,吳中醫藥(轉讓方)將其研發項目重組人血管內皮抑素注射液轉讓給索元生物(受讓方),受讓方負責區域外研發、生產、銷售及以其他方式開發利用重組人血管皮抑素注射液和診斷產品;轉讓方獲得受讓方獨家免費許可,在區域內研發、生產和銷售重組人血管內皮抑素注射液。其中“區域”指中國,包括香港、澳門和台灣。

此次交易採用里程碑付款加銷售提成方式,里程碑款項需在實現對應的裏程碑事件後支付,里程碑款項共計3.13億元人民幣。

索元生物是一家新型、以快速有效的模式開發一類新藥的全球領先型生物醫藥研發公司,利用全基因組掃描及獨特的生物標記物研發技術在臨牀樣本中找到可預測藥物療效的生物標記物,通過這些新發現的生物標記物作為伴隨診斷來篩選患者,發現對內皮抑素敏感的腫瘤患者,從而重新開展臨牀試驗。此次與索元生物的合作可提高新藥開發的成功率,滿足臨牀治療需求,改善腫瘤患者生存獲益,實現雙方共贏。此次交易採用里程碑付款加銷售提成方式,此次協議簽署事項對公司當期財務狀況和經營成果不構成重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account